Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The purpose is to evaluate the effectiveness and safety of fosaprepitant plus ondansetron with dexamethasone or placebo plus ondansetron with dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) with MEC/HE multi-day chemotherapy in children with solid tumors.
Epistemonikos ID: ea40ce5a66367c9cf02e5bda91ea80577ef1311c
First added on: May 07, 2024